These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32802609)

  • 21. Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban.
    Abuan I; Wong KH; Bolinske B; Hale KS
    J Pharm Technol; 2019 Jun; 35(3):119-125. PubMed ID: 34860981
    [No Abstract]   [Full Text] [Related]  

  • 22. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.
    Carpenter E; Singh D; Dietrich E; Gums J
    Ther Adv Drug Saf; 2019; 10():2042098619888133. PubMed ID: 31807265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
    Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
    Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
    Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ;
    Thromb Haemost; 2022 Jun; 122(6):998-1005. PubMed ID: 34996121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new strategy for uncontrollable bleeding after treatment with rivaroxaban or apixaban.
    Kessler CM; Goldstein JN
    Clin Adv Hematol Oncol; 2019 Sep; 17 Suppl 15(9):1-20. PubMed ID: 33843889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
    Sartori M; Cosmi B
    J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists.
    Rodriguez V; Stanek J; Kerlin BA; Dunn AL
    Clin Appl Thromb Hemost; 2022; 28():10760296221078842. PubMed ID: 35275498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Andexanet Alfa and its Clinical Application.
    Noordergraaf FA; Alings M
    Heart Int; 2020; 14(1):20-23. PubMed ID: 36277667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ;
    N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 31. Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital.
    Sobolewski KA; Brophy A; Choi SC; Opsha Y
    Crit Care Explor; 2021 Apr; 3(4):e0356. PubMed ID: 33834167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heparin Resistance After Administration of Andexanet Alfa:Report of a Case].
    Aratame A; Baba T; Minamimura H; Nishimoto Y; Nangoya R
    Kyobu Geka; 2024 Jun; 77(6):454-456. PubMed ID: 39009541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Andexanet alfa (ONDEXXYA
    Yajima T; Higashimori M; Takata C; Sasabe T
    Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversing factor Xa inhibitors - clinical utility of andexanet alfa.
    Kaatz S; Bhansali H; Gibbs J; Lavender R; Mahan CE; Paje DG
    J Blood Med; 2017; 8():141-149. PubMed ID: 28979172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban.
    Eche IM; Elsamadisi P; Wex N; Wyers MC; Brat GA; Cunningham K; Bauer KA
    Pharmacotherapy; 2019 Aug; 39(8):861-865. PubMed ID: 31251821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
    Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
    Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Andexanet alfa for the treatment of hemorrhage.
    Cervi A; Crowther M
    Expert Rev Hematol; 2018 Nov; 11(11):847-855. PubMed ID: 30296870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
    Coleman CI; Dobesh PP; Danese S; Ulloa J; Lovelace B
    Future Cardiol; 2021 Jan; 17(1):127-135. PubMed ID: 32618210
    [No Abstract]   [Full Text] [Related]  

  • 40. Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model.
    Grottke O; Braunschweig T; Rossaint R; Akman N; Leeds JM; Conley PB; Honickel M
    Br J Anaesth; 2019 Aug; 123(2):186-195. PubMed ID: 31202564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.